<DOC>
	<DOCNO>NCT02926456</DOCNO>
	<brief_summary>The purpose study describe effectiveness darunavir/cobicistat ( DRV/c ) -based regimen , measure maintenance virological suppression 48 week baseline , define day treatment DRV/c-based regimen start , collection daily practice data Italian setting .</brief_summary>
	<brief_title>Study HIV1-Positive , Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors ( PI/r ) Starting Cobicistat-Boosted Darunavir ( DRV/c - Rezolsta )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Adult great equal ( &gt; =18 year ) , male female patient Documented Human Immunodeficiency Virus1 ( HIV1 ) infection Eligible darunavir/cobicistat ( DRV/c ) treatment accord Summary Product Characteristics Patients able understand nature study provide consent voluntarily sign Informed Consent Form ( ICF ) allow data collection source data verification accordance local requirement Patients stable ( &gt; = 12 month ) treatment Antiretroviral ( ARV ) therapy PI/ritonavir ( PI/r ) base , prescribe Rezolsta ( DRV/c ) treat physician Patients virosuppressed ( HIVRNA less [ &lt; ] 50 copies/milliliters ) since least 6 month , within HIV treatment moment enrollment ; single value HIVRNA [ &gt; ] 50 copies/ml confirm ( blip ) consider acceptable ; last value collect &lt; 50 copies/ml Patient currently enrol interventional study Patient currently enrol observational study sponsor support Janssen Estimated Glomerular Filtration Rate ( eGFR ) &lt; 70 milliliter per minute ( ml/min ) coadministered agent ( example emtricitabine , lamivudine , tenofovir disoproxil fumarate , adefovir dipivoxil ) require dose adjustment base creatinine clearance Pregnancy breast feed enrollment Allergy intolerance sulphonamides Switch darunavir/ritonavir ( DRV/r ) 600/100 bi die ( bid ) Patient currently mono PI/r therapy Patients treat within one year Direct Acting Antivirals ( DAAs ) Hepatitis C Virus ( HCV ) infection Chemotherapy schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>